Mirum Pharmaceuticals, Inc.

NASDAQ:MIRM

Biotechnology

Healthcare
$92.49 +3.81%

+$3.89 today

Market cap
$6.04B
Beta
0.51
P/E (TTM)
-7.8
EPS (TTM)
-$13.57
52W Low $47.89High $114.99

Volume 0.50M

Average 0.95M

MIRM Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Mirum Pharmaceuticals, Inc.NASDAQ: MIRM

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income growth accelerates

Q2 FY2026 net income of $857.38M (cash outflow) rose 14528.6% year over year, ahead of the +2718.1% change in trailing-twelve-month net income. Sequentially, it rose 8.5% from the prior quarter. Over 3 fiscal years it compounded at -44.4% a year.

Context

  • Net income amounted to 4.5% of revenue in FY2025, down 21.6 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 9 analysts of -$754.61M (+3129.9%) for the fiscal year ending Dec 2026, a step up from the -73.4% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$857.38M+8.5% QoQ
Last fiscal yearDec 2025
-$23.36M-73.4% YoY
LTMJun 2026
-$1.65B+2718.1% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14528.6%-1206.9%-15735.5 pp
1 year-73.4%+3129.9%+3203.4 pp
3-year CAGR-44.4%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(23.36M) USD
Year-over-year change
+73.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How MIRM compares with its peers on the latest reported figures

  • MIRM's LTM Jun 2026 net income of $1.65B is the largest of the 8 companies compared; the peer median is $146.22M.
  • Its year-over-year change of +2718.1% is the highest of 8, against a peer median of +10.8%.
  • Net income amounts to 267.0% of revenue for MIRM, versus a peer median of 91.0%.
MIRM Competitors Peer median
Net Income for MIRM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MIRMMirum Pharmaceuticals, Inc.LTM Jun 2026$1.65B +2718.1%-44.4%267.0%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$608.92M +10.8%-6.7%91.0%
AGIOAgios Pharmaceuticals, Inc.LTM Mar 2026$422.6M -163.5%+21.2%639.8%
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026$325.1M +15.3%-0.8%25.3%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$146.22M +65.1%-57.4%22.5%
ALTAltimmune, Inc.LTM Mar 2026$91.08M +0.9%+1.3%253002.8%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$78.67M +15.4%—173.5%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$61.98M -35.7%-12.4%89.6%
Peer median (excluding MIRM) $146.22M+10.8%-3.7%91.0%

Competitors are the stored peer set for MIRM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(83.99M)(135.67M)(163.42M)(87.94M)(23.36M)
Depreciation & Amortization975K3.24M10.83M23.63M24.24M
Deferred Income Tax595K(6.58M)000
Stock-Based Compensation23.09M27.01M35.02M48.44M71.42M
Change in Working Capital16.98M(21.05M)(22.64M)22.59M(19.72M)
Accounts Receivables0(20.73M)(43.97M)(11.43M)(48.06M)
Inventory(495K)(3.45M)(4.39M)(3.17M)(8.45M)
Accounts Payables22.66M7.64M30.78M40.31M50.1M
Other Working Capital(5.18M)(4.51M)(5.05M)(3.13M)(13.32M)
Other Non-Cash Items(90.41M)12.91M69.26M3.6M3.24M
Operating Cash Flow(132.76M)(120.14M)(70.94M)10.33M55.83M
Capital Expenditures(19.02M)(278K)(20.11M)(993K)(954K)
Acquisitions (Net)(19M)(7.98M)(212.76M)00
Purchases of Investments(198.03M)(132.32M)(27.33M)(89.03M)(97.43M)
Sales of Investments157.6M140.3M153M19.89M74.43M
Other Investing Activities127M7.98M(20M)(20M)0
Investing Cash Flow48.55M7.7M(107.2M)(90.13M)(23.95M)
Debt Repayment00305.3M00
Common Stock Issued6.91M107.37M216.68M17.7M40.14M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities66.55M1.72M(185.39M)00
Financing Cash Flow73.47M109.09M336.6M17.7M40.14M
Effect of Forex Changes(1K)12K(133K)(1.3M)3.22M
Net Change in Cash(10.75M)(3.34M)158.32M(63.4M)75.24M
Free Cash Flow(151.78M)(120.41M)(91.05M)9.33M54.87M

Mirum Pharmaceuticals, Inc.

NASDAQ:MIRM

Intrinsic Alpha fair value

Locked

Current Price

$92.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.